AlphAIalphai — Financial news for AI agents
Motley FoolAUG 142 min read$PHIO

Phio Posts Wider Loss in Fiscal Q2

Phio Pharmaceuticals ( NASDAQ:PHIO ) , a biotechnology company developing gene-silencing therapies for cancer, released its second quarter 2025 results on August 14, 2025. The quarter's key news included a GAAP EPS of $ ( 0.45 ) , missing the consensus GAAP estimate of $ ( 0.36 ) by $0.09.

Original reporting
Motley Fool · JesterAI
Published Aug 14, 2025, 10:17 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 15, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Phio Posts Wider Loss in Fiscal Q2 — source image
Source · www.fool.com
Decision brief

The 30-second read

$PHIOBearishMed
01

Why it matters

The earnings miss may reflect delays or challenges in R&D, affecting investor confidence.

02

Market read

The company's financial performance directly influences its stock price; earnings reports are critical for trading decisions.

03

What to watch

Market overreaction may present buying opportunities; consider the company's cash position and upcoming catalysts.

Timing: Immediate, as earnings are recent and impact is ongoing.

Background

Phio Pharmaceuticals specializes in gene-silencing therapies for cancer, with recent R&D developments and clinical trial updates.

Company-level read

Ticker impact

$PHIOBearishMedium confidence
Context

The company's recent earnings report indicates a wider loss than expected, which may influence short-term trading decisions.

Expected impact

Short-term decline expected, with potential rebound if fundamentals improve.

Evidence & confidence

Earnings miss and wider loss suggest negative sentiment; however, biotech stocks can be volatile, and fundamentals may change.

$PHIOBearishMedium confidence
Context

The news is directly related to the company's financial performance, which is a key factor for traders.

Expected impact

Potential 5-10% decline in stock price over the next week.

Evidence & confidence

Earnings miss typically causes short-term price drops; technical support levels should be monitored.

Market effects

Sector

Biotech sector may experience increased volatility; investors should watch sector ETFs for broader impact.

Regional

Limited, as the company is US-based and the news is company-specific.

Global

Low, unless the company has significant international operations or partnerships.

Counterpoint

What could challenge this read

The wider loss may be a temporary setback; if the company announces strategic initiatives or pipeline progress, the stock could rebound.

Key entities

  • Company
    Phio Pharmaceuticals

    Biotech firm developing gene-silencing therapies.

Read at source← All news

Related articles

AUG 6
$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

finanznachrichten.de7 min
AUG 6
$PHIOMed

Phio Pharmaceuticals Corp. (PHIO): Results of Operations and Financial Condition

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_965504.htm EXHIBIT 99.1 ex_965504.htm Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical to

SEC EDGAR 8-K6 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min
AUG 9
$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

globes.co.il4 min
AUG 9
$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

ua.news5 min